Your browser doesn't support javascript.
loading
Biobanking in the COVID-19 Era and Beyond: Part 2. A Set of Tool Implementation Case Studies.
Allocca, Clare M; Snapes, Emma; Albert, Monique; Bledsoe, Marianna J; Castelhano, Marta G; De Wilde, Mieke; Furuta, Koh; Kozlakidis, Zisis; Martin, Dunja; Martins, Anabela; McCall, Shannon J; Schacter, Brent.
Affiliation
  • Allocca CM; Standards Coordination Office, National Institute of Standards and Technology, Gaithersburg, Maryland, USA.
  • Snapes E; BioConsulting, Cork, Ireland.
  • Albert M; Ontario Tumour Bank, Ontario Institute for Cancer Research, Toronto, Canada.
  • Bledsoe MJ; Biopreservation and Biobanking, Colorado Springs, Colorado, USA.
  • Castelhano MG; Cornell Veterinary Biobank, College of Veterinary Medicine, Cornell University, Ithaca, New York, USA.
  • De Wilde M; Biobank Antwerp, UZA-UAntwerpen, Antwerp, Belgium.
  • Furuta K; Urayasu Warakuen Clinic, Urayasu, Japan.
  • Kozlakidis Z; International Agency for Research on Cancer, World Health Organization, Lyon, France.
  • Martin D; International Agency for Research on Cancer, World Health Organization, Lyon, France.
  • Martins A; Leibniz Institute DSMZ-German Collection of Microorganisms and Cell Cultures GmbH, Braunschweig, Germany.
  • McCall SJ; Micoteca da Universidade do Minho, Centro de Engenharia Biológica, Braga, Portugal.
  • Schacter B; Duke University, Durham, North Carolina, USA.
Biopreserv Biobank ; 18(6): 547-560, 2020 Dec.
Article in En | MEDLINE | ID: mdl-33226280
ABSTRACT
The COVID-19 era has brought about a number of novel challenges for the global biobanking community. An array of diverse tools (e.g., standards, best practices, and plans) exists to support quality and fitness-for-purpose in biobank operations. The International Society for Biological and Environmental Repositories (ISBER) COVID-19 Response Task Force has set out to identify needs and gaps in these tools and make recommendations for the next generation of available tools, having closely examined the COVID-19-related challenges. While conducting this work to examine the relationships between tools and biobank adaptability, a subgroup of the task force conducted a parallel effort to develop and describe individual COVID-19 era case studies based on a number of operating biobanks. Each case study presents a different combination of implemented tools. Observations and lessons learned from these case studies are provided, and experiences with tool implementation are discussed. This information is supplemented by data relating to tool usefulness that was obtained through an ISBER survey discussed in a companion article. The knowledge gained from this study will be combined with other task force efforts to make recommendations to better position the biobanking community in their response to future emergencies.
Subject(s)
Key words

Full text: 1 Database: MEDLINE Main subject: Biological Specimen Banks / Biomedical Research / Pandemics / SARS-CoV-2 / COVID-19 Type of study: Guideline Limits: Humans Language: En Journal: Biopreserv Biobank Year: 2020 Type: Article Affiliation country: United States

Full text: 1 Database: MEDLINE Main subject: Biological Specimen Banks / Biomedical Research / Pandemics / SARS-CoV-2 / COVID-19 Type of study: Guideline Limits: Humans Language: En Journal: Biopreserv Biobank Year: 2020 Type: Article Affiliation country: United States